By Fineline Cube Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its second-generation pan-TRK inhibitor, ICP-723, in pediatric patients aged 2 to 12 years. This follows the drug’s previous entry into clinical studies for adolescents aged 12 to 18 and its demonstration of a good safety and efficacy profile in adult trials.
Expanding Clinical Trials for ICP-723
Zurletrectinib, a Category 1 drug with global intellectual property rights owned by InnoCare, is under development to treat solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. This includes a range of cancers such as breast, colorectal, lung, and thyroid. The drug is particularly targeted at patients who have developed resistance to first-generation TRK inhibitors. NTRK gene fusions are more commonly found in pediatric cancer patients, making the expansion of ICP-723’s clinical trials to this age group a significant step in addressing their treatment needs.-Fineline Info & Tech